The results of an allergen POC trial in asthmatics will summarized by Dr. David Ramos, principal investigator of the PBF-680 clinical program, in an oral presentation titled:
PBF-680, an oral A1 adenosine receptor antagonist, inhibits the late allergic response (LAR) in mild-to-moderate atopic asthmatics: a Phase-IIa trial.
The study concluded that in mild-to-moderate asthmatics, PBF-680 abrogated the LAR, and reduced the EAR, FeNO, and, remarkably, blood eosinophils, with correct safety profile. The data position the adenosine modulator PBF-680 as a promising oral asthma therapy.
La mejor actitud que podemos adoptar es la de trat...
El equipo de investigadores observó cambios en el...
El gen AtCDF3 promueve una mayor producción de az...
En nuestro post hablamos sobre este interesante tipo de célula del si...
Un artículo publicado en Alzheimer’s & Dementia: The Journal of the...
